BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

GHIT Fund Commits USD 4.6 Million to Tackle TB and Neglected Diseases in Low- and Middle-Income Regions

The Global Health Innovative Technology (GHIT) Fund announced an investment of approximately JPY 679 million (USD 4.5 million) for the...

April 23, 2025 | News

University of Melbourne and Thermo Fisher Forge Strategic Partnership to Advance Research Across Healthcare, Manufacturing, and Sustainability

Researchers will be able to access cutting-edge tools to tackle society’s most pressing challenges across healthcare, manufacturing and sustainabilit...

April 22, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Atmo Biosciences Secures Full Ownership of Core IP for Ingestible Gas-Sensing Capsule

Atmo secures full ownership of core IP for its ingestible gas-sensing capsule • RMIT University transfers all patents and IP in exchange for an eq...

April 15, 2025 | News

GPC-100, a CXCR4 Inhibitor, Moves Toward AML Trials Following Promising Preclinical and Phase 1 Data; Phase 2 in Multiple Myeloma Ongoing

Exicure, Inc. shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning f...

April 14, 2025 | News

Thermo Fisher Scientific and NSG BIO Join Forces to Boost Singapore’s Biotech Innovation

The collaboration aims to provide advanced resources and scientific expertise to accelerate innovation and drive sustainable growth Thermo Fisher Sc...

April 09, 2025 | News

ABL Bio and GSK Sign Multi-Program Licensing Deal to Develop Neurodegenerative Therapies Using Grabody-B Platform

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL...

April 07, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Lunit Collaborates with U.S. National Cancer Institute to Advance AI-Driven Cancer Research

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the Nationa...

April 01, 2025 | News

Thermo Fisher Scientific and CZ Imaging Institute Forge Alliance to Advance High-Resolution Cellular Imaging

New alliance for advanced biological imaging aimed at enhancing some of the world's most innovative structural cell biology capabilities to help scientists...

March 28, 2025 | News

Thermo Fisher Scientific Launches IVDR-Compliant SeqStudio™ Flex Dx to Elevate Clinical Lab Performance

— Thermo Fisher Scientific, the world leader in serving science, has announced the launch of the Applied Biosystems™ SeqStudio™ Flex Dx G...

March 26, 2025 | News

Thermo Fisher Scientific Launches Next-Gen HLA Typing Kit to Advance Immunogenetics Research

To enable human leukocyte antigen (HLA) scientists and researchers to continue to advance research of histocompatibility and immunogenetics, Thermo Fisher ...

March 25, 2025 | News

Stay Connected